Abstract -High throughput biological experiments such as DNA Microarrays are very powerful tools to understand and characterize multiple illnesses. These types of experiments, however, have also been described as large, complex, expensive and hard to analyze. For these reasons, analyses with linear assumptions are frequently bypassed for more sophisticated procedures with higher complexity. In this work, a search procedure for potential biomarkers using data from microarray experiments is proposed under purely linear assumptions. The method shows a high discrimination rate and does not require the adjustment of parameters by the user, thus preserving analysis objectivity and repeatability. A case study in the identification of potential biomarkers for cervix cancer is presented to illustrate the application of the proposed procedure.
I. INTRODUCTION
The search for genes whose measured change in expression behavior is an indication of a tissue being in a particular state (e.g. in a state of cancer vs. a state of health) is an important research objective in biology and the medical sciences. These genes are known as biomarkers. Microarray experiments play an important role in the identification of this type of genes. In the successful identification of potential biomarker genes, lies an important characterization of the cell in the presence of cancer. This can lead to enhance disease diagnosis and prognosis capabilities.
Based on our own experience with microarray data, the following challenges regarding microarray experiments can be identified: (1) the available data is highly dimensional in terms of the number of genes to be studied (~104) while showing a scarce number of replicates, (2) there is a rather large variation across replicates, (3) the data is not normally distributed and does not exhibit homogeneous variances, (4) there is a considerable number of missing observations in the majority of experiments, (5) the data is commonly found already being normalized or nonlinearly transformed. All of these complicate the detection of potential biomarkers.
Furthermore, when it comes to data analyses, the following are also important challenges: (i) there is no standard way to compare results for gene selection or identification between studies, (ii) even with the same data (and sometimes with the same technique) different researchers end up with different screening of genes [Ein-dor, et al. 2005 ] thereby leading to a large number of potential biomarkers to be investigated, the research of which could prove lengthy and very expensive.
Truly integrated work across disciplines is not frequent in most microarray analysis works. Biology and Medicine experts are usually left with the burden of using coded analysis tools with a series of parameters -of statistical, computational or mathematical nature/ that significantly affect the outcome of the software packages [Pan, 2002] . This leads to issues in results reproducibility and comparability between studies.
These challenges motivate the search for microarray analysis techniques from which consistent results can be achieved across several experiments and users, particularly for the identification of potential biomarkers.
The purpose of this work is to introduce an approach to identify potential biomarkers from the analysis of microarray experiments based solely on linear models and assumptions. Although an initial purpose on the design of the method was to establish a baseline of comparison for the many sophisticated methods with underlying nonlinear assumptions, it soon became apparent that a very effective strategy might be based on linearity.
II.
THE ANALYSIS STRATEGY Figure 1 schematically shows the strategy proposed in this work. Each step is explained below.
Step 1: Microarray Experiment. The process begins with a microarray experiment with m1 tissues in state one (Healthy) and m2 tissues in state two (Cancer) characterized in n genes. In the intersection of each of the n genes with each of the m1+m2 tissues, the relative expression of that particular gene in the selected tissue is quantified.
Step 2: Represent each gene with multiple performance measures. In this work, the use of a p_values is advocated to represent each gene. A p_value can be computed from the application of a statistical comparison test, like the MannWhitney nonparametric test for difference of medians. A different p_value for the same gene can be obtained by removing a couple of tissues from the microarray experiment under analysis. In a comparison of medians, a low p_value indicates a high probability for the medians to be significantly different.
Step 3: Apply Data Envelopment Analysis. Data Envelopment Analysis (DEA) finds the convex envelop of a particular data set consistently and without the need of varying parameters manually. If, for example, two p_values were used to represent each of the n genes in the experiment, then DEA can be used to find the envelope conformed by the dominating genes following the minimization direction of both p_values. Finding such envelope is done through the application of a linear programming formulation, which is the first instance where linearity becomes useful.
Step 4: Select genes in a series of efficient frontiers. The envelopes found through DEA are formally known as efficient frontiers. When an efficient frontier is found, then the solutions lying on it can be removed (as a layer of an onion), to then find the efficient frontier right underneath it. Following this scheme, several layers can be chosen containing different numbers of genes. These genes, having been found through the minimization of their p_values, are the most likely candidates to be biomarkers. These will be referred to as efficient genes.
Step 5: Create an experimental design to vary the efficient genes. An experimental design using as controllable variables the presence of the genes can be constructed. Each variable can take a value of 0 or 1 (0 for absence of the gene). This experimental design will prescribe a limited number of runs to measure a particular response of interest. In this case, one run corresponds to a combination of efficient genes.
Step 6: At each experimental design point, measure classification performance through linear discriminant analysis. Using the experimental design from the previous step, at each combination of efficient genes it is possible to obtain a measure of classification performance using a linear classifier through linear discriminant analysis. A linear classifier of this kind will always converge to the same position, thus preserving consistent results. At this point, then, a complete experimental design relating the classification rate with the absence or presence of the potential biomarkers is available.
Step 7: Fit a 1st order linear regression model. With the complete experimental design, it is possible to fit a 1st order linear regression model. This model will relate classification performance (response) to the absence or presence of the efficient genes (independent variables).
Step 8: Apply integer linear programming to choose the potential biomarkers that maximize classification performance. An optimization problem can be set up in this stage. This problem entails finding the combination of efficient genes -recall that each gene is represented by a variable that can take values of 0 or 1 to indicate absence or presence of that gene-,that maximizes the classification performance, i.e. choose the genes that maximize the regression model from the previous step.
This procedure, as it was explained, uses only linear models. Because of the techniques chosen in the strategy, the results are consistent. Furthermore, the selected genes do not depend upon the setting of any parameters by the user. This favors the repeatability and auditability of the analysis. 
III. CASE STUDY ON CERVIX CANCER
This case study helps to illustrate the application and the performance of the proposed procedure.
Step 1. The microarray database under analysis is related to cervix cancer and was compiled by Wong et al [3] . The database consists of 8 healthy tissues and 25 cervix cancer tissues, all of them with expression level readings for 10,690 genes.
Step 2. The Mann-Whitney nonparametric two-sided test for comparison of medians was used to generate two different p_values per gene, following a leave-one-tissue-out strategy, which focuses on extracting a particular tissue associated with one state. By removing a vector, a replicate is deleted from the set, thereby forcing a p_value that is different to the original one. Thus, two different p_values are effectively created. The selection of the tissue to be removed to create a distinct matrix is performed randomly as a first approach.
Step 3. The Data Envelopment Analysis model used for this case study was the Banks-Charnes-Cooper (BCC) model [4] . This is a linear programming model with the following associated formulations:
The optimal values of the decision variables correspond to the interceptor and the partial first derivatives (with respect of each performance measure involved) of a supporting hyper plane lying on top of extreme points of the data set under analysis. At the end of the analysis, a piece-wise frontier is distinguishable as shown in Figure 3 . Step 4. The first ten frontiers were kept for this analysis containing a total of 28 genes. It is important to note the discrimination rate shown by the method already at this point: a reduction of four orders of magnitude in the number of genes to analyze.
Step 5. In this step a composite experimental design involving 28 binary variables (one per gene in the shortlist from the previous step), was created and used. In it are a series of combinations (also called runs) that represent the importance of specific genes (named potential biomarkers) and their expression in cancerous or healthy tissues. The experimental design consisted of 123 different runs in which each gene could take a value of 0 (absence) or 1 (presence). In each run the contribution of each gene to detect each tissue is quantified, may it be a set of genes or a gene by itself. Three different experimental designs form the total of 123 runs. The first design is an orthogonal array consisting on 47 runs with between 10 to 18 genes each; the second design has 48 runs with between 1 to 26 genes generated randomly; and the third design consisted of 28 runs, each with only one gene. Figures  4, 5 and 6 show the resulting designs. Step 6. A linear discriminant analysis was carried out using the combination of genes prescribed by each run of the composite design to record the classification performance of a linear classifier. Depending on the absence and presence of certain genes in each run a range of different classification performances will result. It is expected that if the biomarkers are efficient and the more genes present in a specific run, the better the model will classify the tissue (healthy or cancerous). Using an analogy, given the most characteristics possible of a person the better to identify the person will be. However each single gene is also being tested for this analysis and it should be noted that their contribution to the classification performance was more than sufficient (See DOE 3 for detailed information). Step 7. With the experimental design complete, a linear regression of the classification performance as a function of the presence or absence of the 28 genes is built.
Noticing that most of the Classification Performances give a 100% classification, two different regression models were made (from two different samples). The first included all of the 123 original runs from the experimental designs and by consequent the 123 classification performances. For the second model, the sample was reduced to only 38 runs, using the 28 runs from DOE 3 and 10 random ones from DOE 2. By doing this a hierarchy of the genes can be extracted. With the regression, the relationship between each "important" gene and the classification performance can be seen in a linear and simple way. Equation 1 shows the relationship between the classification performance (response) and genes (independent variables). Equation 2 shows the genes belong to a binary set. Table 4 represents the first regression model. It shows that in order to obtain a classification performance of a 100% at least 23 different specific genes are needed. This behavior comes from the small variability in the classification performances for the 123 runs. To obtain a yet better and simpler model we reduced the dataset used for the regression as explained before. After reducing the dataset to only 38 runs the model becomes more targeting, for it now has added variability to it. The model represented in Table 5 , shows that in order to obtain a 10% classification performance only 17 genes are needed. It also shows like the first model the specific genes in order to obtain it.
Step 8. Using the two linear regression models described before, the optimization model is to find the combination of genes (through the use of binary variables) to maximize the predicted classification performance using Linear Integer Programming. Equation 3 shows the objective function and its constraints. Such optimization resulted in the identification of 17 important genes, that is, potential cervix cancer biomarkers. Also, a hierarchy of genes can be found using this procedure which helps visualize exactly what genes and in which order are most necessary and significant when it comes to detect Cervix Cancer.
Shown in Table 7 are the 17 potential biomarkers drawn from the second model. Also the hierarchy and the classification performance are shown, after adding the subsequent gene to the model. CP_Predicted come from the Classification Performance obtained using the Linear Regression from model 2. CP_Real is the Classification Performance obtained by applying LDA method 
IV. VALIDATION STUDY ON COLON CANCER
As part of our study and to reinforce the performance of the proposed method we proceeded to validate the steps illustrated before with other microarray database.
In this validation part the microarray database under analysis was related to colon cancer. A different cancer type database was chosen to prove the effectiveness of the method among different types of cancer. This database consisted of 22 healthy tissues and 40 colon cancer tissues, all of them with expression level readings of 2000 genes. We kept only 27 genes of the 2000 original genes prevenient of the first ten frontiers founded through DEA. Table 8 shows the resulting efficient genes prevenient from the DEA analysis. After the identification of these 27 efficient genes, two different experimental designs were created and these 27 efficient genes were used to vary their efficiency. The experimental designs involved 27 binary variables and formed 37 runs. The first design consists of 10 runs with between 18 to 24 genes generated randomly; and the second design consisted of 27 runs, each with only one gene activated. Figures 8 and 9 show the resulting designs. After the completion of the experimental designs a linear regression model was used to relate the classification performance with the absence or presence of each of the 27 efficient genes. The results gave us the identification of 15
Using the two experimental designs we measured and recorded the classification performance through linear discriminant analysis using the different combination of genes given by each run. Results are shown in Table 9 . potential colon cancer biomarkers. This means that to obtain a classification performance of 100% at least these 15 genes are needed. Table 10 shows a list of these potential colon cancer biomarkers. Once completed the linear regression analysis we used this equation to find the combination of genes that maximize the classification performance applying integer linear programming. The use of this tool allowed us to obtain a hierarchy of genes that permit us to know the significance of each potential colon cancer biomarker in the detection of cancer. The hierarchy obtained in the colon cancer study is shown in Table 11 . 
